Colombian president says earthquake death toll has reached 314; 262 people remain missing.

Jefferies analyst Andrew Tsai says a breakthrough in a skin‑cancer vaccine positions Moderna to have more than seven marketed products by 2027-28. He notes the company is diversifying into respiratory drugs, oncology and AI-designed therapeutics. Jefferies projects 2026 revenue could rise up to 10% from $1.9bn in 2025, which could allow Moderna to reach break-even in 2028. Successful trials of Moderna’s experimental mRNA cancer vaccine could drive sales growth beginning in 2027.

Traders say the Reserve Bank of India may be selling dollars to defend the rupee.